ES2073391T3 - Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre. - Google Patents

Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.

Info

Publication number
ES2073391T3
ES2073391T3 ES87309685T ES87309685T ES2073391T3 ES 2073391 T3 ES2073391 T3 ES 2073391T3 ES 87309685 T ES87309685 T ES 87309685T ES 87309685 T ES87309685 T ES 87309685T ES 2073391 T3 ES2073391 T3 ES 2073391T3
Authority
ES
Spain
Prior art keywords
treatment
therapeutic compositions
disorders
blood loss
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87309685T
Other languages
English (en)
Inventor
Donogh Paul O'brien
Gordon Allen Vehar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25453974&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2073391(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2073391T3 publication Critical patent/ES2073391T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

EL USO DE FACTOR DE PROTEINA DE TEJIDOS O SUS ANTAGONISTAS EN COMPOSICIONES TERAPEUTICAS PARA EL TRATAMIENTO DE DESORDENES SANGUINEOS, POR EJEMPLO LOS CARACTERIZADOS POR UNA TENDENCIA HACIA LA HEMORRAGIA O UN ESTADO HIPERCOAGULATIVO.
ES87309685T 1986-11-04 1987-11-02 Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre. Expired - Lifetime ES2073391T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92697786A 1986-11-04 1986-11-04

Publications (1)

Publication Number Publication Date
ES2073391T3 true ES2073391T3 (es) 1995-08-16

Family

ID=25453974

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87309685T Expired - Lifetime ES2073391T3 (es) 1986-11-04 1987-11-02 Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.

Country Status (8)

Country Link
EP (1) EP0266993B1 (es)
JP (1) JP2758162B2 (es)
AT (1) ATE120645T1 (es)
CA (1) CA1317878C (es)
DE (1) DE3751218T2 (es)
ES (1) ES2073391T3 (es)
NZ (1) NZ222434A (es)
ZA (1) ZA878249B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589173A (en) 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
CA2026666A1 (en) * 1989-02-02 1990-08-03 Yukiya Koike Method of detecting human tissue factor active substance
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
KR100565883B1 (ko) 1997-01-22 2006-03-31 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 응고 및 종양 치료용 조직 인자 방법 및 조성물
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
ES2188202T3 (es) 1998-07-13 2003-06-16 Univ Texas Metodos de tratamiento para el cancer usando conjugados terapeuticos que se enlazan con aminofosfolipidos.
US6596847B2 (en) 1998-07-15 2003-07-22 Genentech, Inc. Tissue factor protein variants
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
EP1749536A1 (en) * 2005-08-03 2007-02-07 Thrombotargets Europe, S.L. Activated factor X stimulants as new antihemorrhagic agents for topical use
US7772371B2 (en) 2005-08-03 2010-08-10 Thrombotargets Corporation Stimulators of Factor X activated (FXa) as new topical antihemorrhagic agents
US20180111977A1 (en) * 2015-03-23 2018-04-26 Dana Genetic A/S Recombinant soluble human tissue factor, method of its production and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL64879C (es) * 1944-05-20
DE3150596A1 (de) * 1981-12-21 1983-06-30 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von gewebsthromboplastin

Also Published As

Publication number Publication date
NZ222434A (en) 1990-06-26
JP2758162B2 (ja) 1998-05-28
EP0266993B1 (en) 1995-04-05
ATE120645T1 (de) 1995-04-15
EP0266993A2 (en) 1988-05-11
ZA878249B (en) 1989-07-26
EP0266993A3 (en) 1988-07-27
JPS63218625A (ja) 1988-09-12
DE3751218T2 (de) 1995-11-09
DE3751218D1 (de) 1995-05-11
CA1317878C (en) 1993-05-18

Similar Documents

Publication Publication Date Title
DE69200675T2 (de) Verwendung von Droloxifen bei der Behandlung von Knochenerkrankungen.
DE69010840D1 (de) Sterile chirurgische Nadel-Nähfaden-Zusammensetzung.
DE3854376D1 (de) Nähgerät für arthroskopische Chirurgie.
DE3850914D1 (de) Gerät für die thermische Therapie von Körpergeweben.
DE3587563D1 (de) Absorbierbares Gewebe für chirurgische Eingriffe.
IT8123070A0 (it) Preparato che favorisce la coagulazione del sangue a base di proteine umani, nonche'procedimento per la preparazione
DE3578611D1 (de) Instrumente zur behandlung von verformten naegeln bei menschlichen patienten.
ES2073391T3 (es) Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.
DE68915503T2 (de) Zahnchirurgisches Gerät, geeignet für die Versorgung von gekoppelten Handstücken mit drei unterschiedlichen Fluida.
IT1238825B (it) Dispositivo per la correzione chirurgica dell'ametropia.
IT9041503A0 (it) Dispositivo per la cura chirurgica dell'ametropia
FI913818A0 (fi) Nytt trombolytiskt aemne.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE3687233T2 (de) Pharmazeutische zusammensetzungen zur behandlung von hautkrankheiten.
DE68905076T2 (de) Pharmazeutische Zusammensetzung für die Behandlung von Hautwunden.
DE295827T1 (de) Verwendung von 24,25-dihydroxycholecalciferol bei der heilung von knochenbruechen.
DE3686652T2 (de) 1,3-dithio-2-ylidenemalonate zur heilung von fett-nekrose.
NO880831D0 (no) Rekombinant human vevsplasminogen-aktivatorblanding.
IT8919216A0 (it) Dispositivo per la cura chirurgica dell'astigmatismo.
DE68906028D1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
DE68914886D1 (de) Mittel zur Behandlung von Raynaud's Krankheit.
ATE90547T1 (de) Chirurgisches implantat zum begrenzen der relativbewegung von wirbeln.
IT8609534A0 (it) Preparato,in particolare collirio o pomata,per il trattamento di alterazioni distrofiche e vascolari dei tessuti oculari.
ATE102828T1 (de) Verwendung von calciumantagonisten fuer die behandlung von narben.
MX9203508A (es) 1,7-difenil-3-metilaza -7-ciano-8-metilnonano para usarse en el tratamiento de enfermedades.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 266993

Country of ref document: ES